Showing 1 to 10 of 81
About Kantar Health
Kantar Health is the one organization that healthcare companies can count on to get an informed answer to their product development, launch and brand questions. We combine evidence-based research with deep clinical, commercial and brand expertise to help our clients assess market opportunities, prioritize product development and portfolio activities, and differentiate their products to drive brand success.
Australia Healthcare Profile
Australia’s developed pharmaceutical market and rising healthcare costs present pockets of opportunities and challenges that expert knowledge can tease out.
Biosimilars in China: Market Access and Barriers
This report provides insights into the opportunities and barriers in the Chinese biosimilars market and how to maximize these opportunities and reduce the threats to reap return-on-investment.
Brand Equity Assessment
Kantar Health’s framework for brand growth, PINNAKLE®, uncovers unrealized brand opportunity, measures and optimizes brand performance, and improves customer experience across the product lifecycle.
Brand managers and marketers alike are challenged to maximize brand potential across the product lifecycle. However, in today’s highly fluid marketing environment, many are asking, “Is traditional brand marketing dead?” At Kantar Health, we believe the answer is “no,” even though market dynamics continue to change dramatically.
Business Development & Licensing
The constantly changing pharma market brings unique challenges to your business development and licensing initiatives. Kantar Health offers a wide range of services spanning the business development process - from strategic planning to translation support as well as custom consulting to meet your specific needs.
Cancer Patient 360° - Egypt
Kantar Health Cancer Patient 360° – Egypt is a syndicated study that follows 460 Egyptian cancer patients along their journey. It measures satisfaction with treatment, quality of life and the burden of disease in patients with colorectal cancer (CRC), breast cancer, head and neck cancers, prostate cancer and non-Hodgkin’s lymphoma.
CancerLandscape™ is a web-based platform that allows users to quickly review more than 6,000 cancer drugs simultaneously. It combines multiple primary and secondary data sources so users can quickly navigate product opportunities within the cancer landscape.
CancerMPact® is an invaluable and comprehensive oncology decision support resource. It can be utilized for market analysis, strategic planning and identification of commercial opportunities in the U.S., Western Europe, Japan and China.
CancerMPact® Biomarker Analysis
Biomarker Analysis is a global resource based on a thorough review of literature and recently published data that discusses the current and evolving oncology landscape with regard to biomarker segmentation and geographic, survival, ethnic, racial and gender differences.